Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:TLX News 11 December 2025 - 17 December 2025

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals Limited (ASX:TLX, Nasdaq:TLX) entered the spotlight again on December 17, 2025, as TLX stock extended its December sell-off amid a fast-moving mix of clinical-trial updates, regulatory overhang, and investor litigation headlines. Telix Pharmaceuticals+2Investing.com+2 On the ASX, Telix shares closed at A$11.73, down 6.61% on the session, with a wide intraday range from A$11.535 to A$12.730 and volume of roughly 6.36 million shares—a notably volatile day by recent standards. Investing.com+1 In the U.S., Telix’s Nasdaq-listed shares/ADS were also under pressure, with U.S. market coverage noting a gap-down move and a roughly 6%–7% decline in early trading action on Dec.
17 December 2025
···
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

December 11, 2025 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack of class‑action lawsuits. At the same time, new clinical milestones and a fresh collaboration with Varian are reinforcing the long‑term radiopharmaceutical growth story. This overview pulls together today’s news, the latest clinical and legal developments, and current analyst forecasts as of 11 December 2025. Telix share price today: depressed after a volatile year By midday in New York on 11
11 December 2025
···

Stock Market Today

Moore Threads (688795) share price in focus after Pony.ai tie-up as China market reopens

Moore Threads (688795) share price in focus after Pony.ai tie-up as China market reopens

8 February 2026
Shanghai, Feb 8, 2026, 09:09 GMT+8 — Market closed. Moore Threads Technology Co., Ltd. Class A shares (688795) last closed up 0.45% at 536.99 yuan on Feb. 6, after trading between 523.01 and 542.69 yuan. The close left the stock near the bottom of its 523.01–941.08 yuan 52-week range ahead of Monday’s reopen. (英为财情 Investing.com) The weekend pause gives investors time to weigh whether the Pony.ai tie-up signals real demand, not just another headline, for China’s young domestic GPU names. The broader push for homegrown chips has drawn fresh attention as U.S. export curbs restrict access to advanced AI processors.
NXP stock heads into Monday after $3 billion credit line refresh — what to watch for NXPI

NXP stock heads into Monday after $3 billion credit line refresh — what to watch for NXPI

8 February 2026
NXP Semiconductors shares closed up 1% at $224.32 Friday after subsidiaries amended a $3 billion revolving credit deal with Barclays, maturing in 2031. The PHLX semiconductor index surged 5.7% as chip stocks rallied on AI spending signals from Amazon and Alphabet. NXP’s gain lagged peers like Monolithic Power, which rose 6.4%. Investors await U.S. jobs and inflation data next week.
Go toTop